[Pubmed] Telitacicept for refractory AChR-positive generalized myasthenia gravis: a retrospective real-world study
Posté : 25 févr. 2026 12:00
Front Immunol. 2026 Feb 9;17:1752245. doi: 10.3389/fimmu.2026.1752245. eCollection 2026.
ABSTRACT
BACKGROUND AND AIMS: Treating refractory acetylcholine receptor-positive generalized myasthenia gravis (AChR+ gMG) remains challenging, especially for patients requiring long-term immunosuppressive therapy. Current treatments often lack specificity and pose significant long-term risks, underscoring the need for alternatives. Telitacicept, a novel dual inhibitor of B lymphocyte stimulator (BLyS) and proliferation-inducing ligand (APRIL), offers a promising targeted therapeutic approach. This study aimed to evaluate the efficacy and safety of telitacicept in the treatment of refractory AChR+ generalized myasthenia gravis.
METHODS: This retrospective study included 42 patients with refractory AChR+ gMG who received telitacicept. The primary outcomes assessed were changes from baseline in Quantitative Myasthenia Gravis (QMG) scores, analyzed using mixed-effects models. Secondary outcomes comprised cumulative response rates, reductions in concomitant immunosuppressive medications, and safety events.
RESULTS: A total of 42 refractory MG patients with MGFA class II-IV were enrolled. Significant improvements were observed in the QMG total score (least-squares [LS] mean change at month 5: -2.24, 95% CI -3.34 to -1.15, p
Source: https://pubmed.ncbi.nlm.nih.gov/4173722 ... 22+67771e2